Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

PURPOSE: EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance of EPclin for estimating 10-year distant recurrence-free...

Descripción completa

Detalles Bibliográficos
Autores principales: Sestak, Ivana, Martín, Miguel, Dubsky, Peter, Kronenwett, Ralf, Rojo, Federico, Cuzick, Jack, Filipits, Martin, Ruiz, Amparo, Gradishar, William, Soliman, Hatem, Schwartzberg, Lee, Buus, Richard, Hlauschek, Dominik, Rodríguez-Lescure, Alvaro, Gnant, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555778/
https://www.ncbi.nlm.nih.gov/pubmed/31041683
http://dx.doi.org/10.1007/s10549-019-05226-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555778/
https://www.ncbi.nlm.nih.gov/pubmed/31041683
http://dx.doi.org/10.1007/s10549-019-05226-8

Ejemplares similares